Jennifer S Albrecht1, Yujin Park2, Peter Hur2, Ting-Ying Huang2, Ilene Harris3, Giora Netzer1,4, Susan W Lehmann5, Patricia Langenberg1, Bilal Khokhar2, Yu-Jung Wei6, Patience Moyo2, Linda Simoni-Wastila2. 1. 1 Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. 2. 2 Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland. 3. 3 IMPAQ International LLC, Columbia, Maryland. 4. 4 Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland. 5. 5 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; and. 6. 6 Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida.
Abstract
RATIONALE: Among individuals with chronic obstructive pulmonary disease (COPD), depression is one of the most common yet underrecognized and undertreated comorbidities. Although depression has been associated with reduced adherence to maintenance medications used in other conditions, such as diabetes, little research has assessed the role of depression in COPD medication use and adherence. OBJECTIVES: The objective of this study was to assess the impact of depression on COPD maintenance medication adherence among a nationally representative sample of Medicare beneficiaries newly diagnosed with COPD. METHODS: We used a 5% random sample of Medicare administrative claims data to identify beneficiaries diagnosed with COPD between 2006 and 2010. We included beneficiaries with 2 years of continuous Medicare Parts A, B, and D coverage and at least two prescription fills for COPD maintenance medications after COPD diagnosis. We searched for prescription fills for inhaled corticosteroids, long-acting β-agonists, and long-acting anticholinergics and calculated adherence starting at the first fill. We modeled adherence to COPD maintenance medications as a function of new episodes of depression, using generalized estimated equations. MEASUREMENTS AND MAIN RESULTS: Our primary outcome was adherence to COPD maintenance medications, measured as proportion of days covered. The exposure measure was depression. Both COPD and depression were assessed using diagnostic codes in Part A and B data. Covariates included sociodemographics, as well as clinical markers, including comorbidities, COPD severity, and depression severity. Of 31,033 beneficiaries meeting inclusion criteria, 6,227 (20%) were diagnosed with depression after COPD diagnosis. Average monthly adherence to COPD maintenance medications was low, peaking at 57% in the month after first fill and decreasing to 35% within 6 months. In our adjusted regression model, depression was associated with decreased adherence to COPD maintenance medications (odds ratio, 0.93; 95% confidence interval, 0.89-0.98). CONCLUSIONS: New episodes of depression decreased adherence to maintenance medications used to manage COPD among older adults. Clinicians who treat older adults with COPD should be aware of the development of depression, especially during the first 6 months after COPD diagnosis, and monitor patients' adherence to prescribed COPD medications to ensure best clinical outcomes.
RATIONALE: Among individuals with chronic obstructive pulmonary disease (COPD), depression is one of the most common yet underrecognized and undertreated comorbidities. Although depression has been associated with reduced adherence to maintenance medications used in other conditions, such as diabetes, little research has assessed the role of depression in COPD medication use and adherence. OBJECTIVES: The objective of this study was to assess the impact of depression on COPD maintenance medication adherence among a nationally representative sample of Medicare beneficiaries newly diagnosed with COPD. METHODS: We used a 5% random sample of Medicare administrative claims data to identify beneficiaries diagnosed with COPD between 2006 and 2010. We included beneficiaries with 2 years of continuous Medicare Parts A, B, and D coverage and at least two prescription fills for COPD maintenance medications after COPD diagnosis. We searched for prescription fills for inhaled corticosteroids, long-acting β-agonists, and long-acting anticholinergics and calculated adherence starting at the first fill. We modeled adherence to COPD maintenance medications as a function of new episodes of depression, using generalized estimated equations. MEASUREMENTS AND MAIN RESULTS: Our primary outcome was adherence to COPD maintenance medications, measured as proportion of days covered. The exposure measure was depression. Both COPD and depression were assessed using diagnostic codes in Part A and B data. Covariates included sociodemographics, as well as clinical markers, including comorbidities, COPD severity, and depression severity. Of 31,033 beneficiaries meeting inclusion criteria, 6,227 (20%) were diagnosed with depression after COPD diagnosis. Average monthly adherence to COPD maintenance medications was low, peaking at 57% in the month after first fill and decreasing to 35% within 6 months. In our adjusted regression model, depression was associated with decreased adherence to COPD maintenance medications (odds ratio, 0.93; 95% confidence interval, 0.89-0.98). CONCLUSIONS: New episodes of depression decreased adherence to maintenance medications used to manage COPD among older adults. Clinicians who treat older adults with COPD should be aware of the development of depression, especially during the first 6 months after COPD diagnosis, and monitor patients' adherence to prescribed COPD medications to ensure best clinical outcomes.
Authors: Bruce C Stuart; Linda Simoni-Wastila; Ilene H Zuckerman; Amy Davidoff; Thomas Shaffer; Hui-wen Keri Yang; Jingjing Qian; Anand A Dalal; Douglas W Mapel; Lynda Bryant-Comstock Journal: Am J Geriatr Pharmacother Date: 2010-10
Authors: D A Solomon; M B Keller; A C Leon; T I Mueller; M T Shea; M Warshaw; J D Maser; W Coryell; J Endicott Journal: Arch Gen Psychiatry Date: 1997-11
Authors: Jingjing Qian; Linda Simoni-Wastila; Gail B Rattinger; Ilene H Zuckerman; Susan Lehmann; Yu-Jung J Wei; Bruce Stuart Journal: Int J Geriatr Psychiatry Date: 2013-04-19 Impact factor: 3.485
Authors: Vincent S Fan; Scott D Ramsey; Nicholas D Giardino; Barry J Make; Charles F Emery; Phillip T Diaz; Joshua O Benditt; Zab Mosenifar; Robert McKenna; Jeffrey L Curtis; Alfred P Fishman; Fernando J Martinez Journal: Arch Intern Med Date: 2007-11-26
Authors: Carly M Goldstein; Emily C Gathright; John Gunstad; Mary A Dolansky; Joseph D Redle; Richard Josephson; Shirley M Moore; Joel W Hughes Journal: J Behav Med Date: 2017-02-11
Authors: Jennifer S Albrecht; Bilal Khokhar; Ting-Ying Huang; Yu-Jung Wei; Ilene Harris; Patience Moyo; Peter Hur; Susan W Lehmann; Giora Netzer; Linda Simoni-Wastila Journal: Respir Med Date: 2017-06-03 Impact factor: 3.415
Authors: Cara B Pasquale; Radmila Choate; Gretchen McCreary; Richard A Mularski; William Clark; MaryEllen Houlihan; Elisha Malanga; Barbara P Yawn Journal: Chronic Obstr Pulm Dis Date: 2021-10-28
Authors: Nurdan Kokturk; Mehmet Polatli; I Kivilcim Oguzulgen; Sarfraz Saleemi; Mohammed Al Ghobain; Javed Khan; Adam Doble; Luqman Tariq; Fayaz Aziz; Abdelkader El Hasnaoui Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-04-27
Authors: Faustine Dalon; Nicolas Roche; Manon Belhassen; Maëva Nolin; Hervé Pegliasco; Gaëtan Deslée; Bruno Housset; Philippe Devillier; Eric Van Ganse Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-08-20
Authors: Shari S Rogal; Gautham Mankaney; Viyan Udawatta; Matthew Chinman; Chester B Good; Susan Zickmund; Klaus Bielefeldt; Alexis Chidi; Naudia Jonassaint; Alison Jazwinski; Obaid Shaikh; Christopher Hughes; Paulo Fontes; Abhinav Humar; Andrea DiMartini Journal: PLoS One Date: 2016-11-07 Impact factor: 3.240